NCT06684249 Efficacy of Nerve Block Versus Botox in Chronic Migraine Management
| NCT ID | NCT06684249 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zagazig University |
| Condition | Chronic Migraine |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2024-11-10 |
| Primary Completion | 2025-05-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 64 participants in total. It began in 2024-11-10 with a primary completion date of 2025-05-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine whether nerve block injections (specifically, supratrochlear and greater occipital nerve injections) are as effective as Botulinum toxin A (Botox) injections in treating chronic migraine in adults. The main questions it aims to answer are: * Do nerve block injections reduce the number of monthly migraine days compared to baseline? * Are there any differences in the frequency of migraine-related symptoms between the nerve block and Botox treatment groups? * Which treatment leads to higher patient satisfaction and improved quality of life? Participants in this study will: * Receive either nerve block injections or Botox injections every 12 weeks. * Visit the clinic once every month for follow-ups and assessments. * Maintain a headache diary to record the frequency and severity of their migraines and any adverse effects experienced. * Researchers will compare the outcomes of the two groups to determine if one treatment is superior in terms of efficacy and patient satisfaction.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 65 years. * Diagnosis of chronic migraine, defined as having headaches on 15 or more days per month for more than three months, with at least 8 of those days meeting criteria for migraine. * Ability to provide informed consent and comply with study requirements. * No changes in prophylactic migraine medications in the last 3 months. Exclusion Criteria: * History of allergy or hypersensitivity to local anesthetics or Botulinum toxin. * Previous nerve block or Botox treatment within the last 6 months. * Significant comorbid psychiatric or neurological disorders that could interfere with study participation or evaluation. * Pregnancy or breastfeeding. * Contraindications to either treatment as per product labels.
Contact & Investigator
Ahmed Bessar, MD, PhD
PRINCIPAL INVESTIGATOR
Assistant Professor of Diagnostic and Interventional Radiology, Zagazig Uni.
Frequently Asked Questions
Who can join the NCT06684249 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Chronic Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06684249 currently recruiting?
Yes, NCT06684249 is actively recruiting participants. Contact the research team at Ahmedawadbessar@gmail.com for enrollment information.
Where is the NCT06684249 trial being conducted?
This trial is being conducted at Zagazig, Egypt.
Who is sponsoring the NCT06684249 clinical trial?
NCT06684249 is sponsored by Zagazig University. The principal investigator is Ahmed Bessar, MD, PhD at Assistant Professor of Diagnostic and Interventional Radiology, Zagazig Uni.. The trial plans to enroll 64 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.